Liver resection and ablation for metastatic melanoma: A single center experience Journal Article


Authors: Doussot, A.; Nardin, C.; Takaki, H.; Litchman, T. D.; D'Angelica, M. I.; Jarnagin, W. R.; Postow, M. A.; Erinjeri, J. P.; Kingham, T. P.
Article Title: Liver resection and ablation for metastatic melanoma: A single center experience
Abstract: BACKGROUND The median survival for patients with stage IV metastatic melanoma is usually limited to approximately 1 year. In the case of liver metastasis, resection and ablation can achieve long-term survival. This study aimed to describe the outcomes after liver resection or ablation for metastatic melanoma to the liver and identify preoperative prognostic factors. METHODS Forty eight patients who underwent liver resection (n=32) or percutaneous ablation (n=16) were identified from the 1,523 patients with melanoma liver metastases evaluated between January1993 and January 2013. RESULTS Median OS was 25.9 months. Median OS was not different after ablation (18 months) and resection (26 months; P>0.2). Patients in the ablation group more often presented with extrahepatic disease (EHD) (P=0.008) and received more frequently systemic therapy before ablation (P=0.005). Patients without EHD tended to have longer OS (26.5 vs. 12 months; P=0.076) and PFS (13 vs. 5 months; P=0.11) in the whole cohort. EHD was significantly associated with a worse OS in the resection group (P=0.034). CONCLUSION Liver resection is associated to prolonged survival over 24 months and should be considered only in selected patients with metastatic disease confined to the liver. In patients not candidate for surgery, tumor ablation can be considered. © 2015 Wiley Periodicals, Inc.
Keywords: liver resection; ablation therapy; extrahepatic disease; melanoma liver metastasis
Journal Title: Journal of Surgical Oncology
Volume: 111
Issue: 8
ISSN: 0022-4790
Publisher: Wiley Blackwell  
Date Published: 2015-06-15
Start Page: 962
End Page: 968
Language: English
DOI: 10.1002/jso.23929
PROVIDER: scopus
PUBMED: 26073980
PMCID: PMC5170874
DOI/URL:
Notes: Export Date: 3 August 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michael Andrew Postow
    361 Postow
  2. William R Jarnagin
    903 Jarnagin
  3. T Peter Kingham
    609 Kingham
  4. Joseph Patrick Erinjeri
    200 Erinjeri
  5. Haruyuki Takaki
    7 Takaki
  6. Alexandre Florent Doussot
    15 Doussot